Protalix BioTherapeutics (PLX) Income from Discontinued Operations (2015 - 2016)
Protalix BioTherapeutics (PLX) posted Income from Discontinued Operations of -$117000.0 for Q2 2016, down 62.5% on a QoQ basis from -$72000.0 in Q1 2016, and down 110.52% year-over-year from $1.1 million in Q3 2015.
Powered by 
Analysis
Protalix BioTherapeutics (PLX) Income from Discontinued Operations (2015 - 2016) Analysis & Trends
Protalix BioTherapeutics has reported Income from Discontinued Operations for 2 years, with the latest figure at -$117000.0 in Q2 2016.
- On a quarterly basis, Income from Discontinued Operations fell 110.52% year-over-year to -$117000.0 in Q2 2016; TTM through Mar 2017 was -$117000.0, a 100.14% decrease from a year earlier, with the FY2016 full-year figure at -$189000.0, down 100.22% from the prior year.
- Income from Discontinued Operations was -$117000.0 for Q2 2016 at Protalix BioTherapeutics, down from -$72000.0 in the prior quarter.
- The five-year high for Income from Discontinued Operations was $81.5 million in Q4 2015, with the low at -$117000.0 in Q2 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Protalix BioTherapeutics | 218.36 Mn | 177.71 Mn | 12.13 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2016 | -117,000.00 |
| Mar 31, 2016 | -72,000.00 |
| Dec 31, 2015 | 81.47 Mn |
| Sep 30, 2015 | 2.20 Mn |
| Jun 30, 2015 | 1.11 Mn |
| Mar 31, 2015 | 541,000.00 |